Further studies should elucidate the precise mechanism of HIGD2A activity in the modulation of the MAPK/ERK pathway, and explore the role of HIGD2A in HCC metastasis, and as a feasible to target for liver cancer therapy. The gene discussed is MAPK1; the disease is liver cancer.